pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 3·1 min read
save

Bristol Myers turns focus to AI costs after broad rollout to workers

PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually creating productivity and ...

Jun 3, 2026·read at Endpoints ↗

Chris Boerner, Bristol Myers Squibb CEO June 3, 2026 01:58 PM EDT AIPharma Bris­tol My­ers turns fo­cus to AI costs af­ter broad roll­out to work­ers Drew Armstrong Executive Editor PA­LO AL­TO, CA — Af­ter giv­ing ar­ti­fi­cial in­tel­li­gence tools to thou­sands of em­ploy­ees, Bris­tol My­ers Squibb is now work­ing to get a han­dle on the costs … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
90 words · retrieved Jun 3
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOL3BRISTOL MYERS SQUIBB2BRISTOL MYERS SQUIBB CO2

related stories

  • May 29Bristol Myers unveils data for one of its next-gen blood cancer drugsBioPharma Dive
  • May 29Replimune takes third swing at cancer drug approval following ‘productive’ FDA talksBioPharma Dive
  • May 29Pfizer, Innovent strike $10B cancer drug dealBioPharma Dive
  • May 19STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much moreSTAT
  • May 18STAT+: Supreme Court rejects challenge to Medicare drug price negotiationSTAT